Condition: HPV Infection · Anal Cancer · Sponsor: ANRS, Emerging Infectious Diseases
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
This description comes directly from the study's public registry record.
Fatoumata Coulibaly · 0144236110 · fatoumata.coulibay@inserm.fr
Mathilde Ghislain, MSc · 0145595229 · mathilde.ghislain@inserm.fr
Always discuss trial participation with your own doctor first.
| Hôpital de la Croix Rousse - SMIT | Lyon, France | Recruiting |
| Hôpital Saint-Louis - SMIT | Paris, France | Recruiting |
| Hôpital Tenon - SMIT | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06522256